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Iridium-catalysed C–H borylation of
β-aryl-aminopropionic acids†
Henry Robinson,a Joe Stillibrand,‡a Klemensas Simelis,a Simon J. F. Macdonaldb and
Andrew Nortcliffe *a
Iridium-catalysed catalytic, regioselective C–H borylation of β-aryl-aminopropionic acid derivatives gives
access to 3,5-functionalised protected β-aryl-aminopropionic acid boronates. The synthetic versatility of
these new boronates is demonstrated through sequential one-pot functionalisation reactions to give
diverse building blocks for medicinal chemistry. The C–H borylation is also effective for dipeptide sub-
strates. We have exemplified this methodology in the synthesis of a pan αv integrin antagonist.
Introduction
Natural and non-natural amino acids are widespread and have
been extensively exploited in the synthesis of therapeutic mole-
cules.1 As a result, there is a continued need to develop novel
strategies for the synthesis of these fundamentally important
building blocks. Of particular importance in the context of
medicinal chemistry is the development of methods for the
construction of structurally diverse β-aryl-aminopropionic
acids. This motif is present in biologically active molecules
with activity against Chagas disease,2 breast cancer,3 and in αv
integrin antagonists as potential treatments for osteoporosis,4
melanoma5 and idiopathic pulmonary fibrosis.6 Additionally,
β-phenyl-aminopropionic acid is an intermediate in the syn-
thesis of Maraviroc,7 a CCR-5 receptor antagonist used for the
treatment and prevention of HIV. Therefore, a unified strategy
to the synthesis of functionalised β-aryl-aminopropionic acid
would be of significant value.
Three general strategies have been developed for the syn-
thesis of β-aryl-aminopropionic acids to date (Scheme 1). The
Rodionov reaction (Scheme 1A) represents the simplest option
and involves the multicomponent coupling of an aldehyde,
malonic acid and ammonium acetate to generate racemic
β-aryl-aminopropionic acids.8–10 A second protocol involves
diastereoselective Reformatsky reactions of sulfinimines
(Scheme 1B).11 An alternative auxiliary-based approach is
depicted in Scheme 1C and involves the addition of chiral
lithium amides to cinnamic acid derivatives (Scheme 1C).12–14
These strategies for the synthesis of β-aryl-aminopropionic
acids are dependent on the availability of highly functionalised
starting aldehydes (Scheme 1A and B) or aryl bromides
(Scheme 1C). While some of these are commercially available,
they are available in limited supply and, since the diversity is
introduced in the first step, a multistep synthesis is required
for each different β-aryl-aminopropionic acid. This makes the
exploration of structure–activity relationships around the aryl
ring time and resource consuming.
As part of our research into novel biologically active pepti-
domimetics for therapeutic application we sought to incorpor-
ate β-aryl-aminopropionic acids with diverse substituents in
the 3- and 5-positions. Given that existing methods, require a
bespoke aldehyde or aryl bromide for every new compound
and we designed an alternative method based on a late-stage
functionalisation approach. Specifically, we envisioned that an
appropriately pre-functionalised 3-substituted β-aryl-aminopro-
pionic acid derivative, accessed via a Rodionov multicompo-
nent reaction from more widely available 3-substituted alde-
hyde, could undergo a C–H functionalisation reactions
(Scheme 2) providing a platform for further chemistry.
In the past decade C–H activation chemistry emerged into
the forefront of modern organic chemistry. The innovative
work of Hartwig and Miyaura,15 and Smith and Maleczka16 in
iridium-catalysed aromatic C–H borylation offers a potentially
powerful method for functionalisation given that the synthetic
versatility of boronate groups is ever increasing.17–19
Encouraged by previous examples of C–H borylation on
simple phenylalanine20 and tryptophan21 derivatives we now
report the substrate directed iridium borylation of β-3-aryl-ami-
nopropionic acid precursors together with examples of “one-
pot” transformations to diversely functionalised 3,5-substi-
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tuted products and implementation of this methodology in
the preparation of an integrin antagonist bearing a β-3,5-aryl-
aminopropionic acid motif.
Results and discussion
A series of 3-substituted β-aryl-aminopropionic acid derivatives
were prepared by Rodionov multicomponent reaction or
addition of the bromozincacetate to the corresponding sulfini-
mine followed by suitable protection as the N-Boc esters. Using
1d as a model substrate we performed a brief screen of pre-
viously reported ligands and solvents to determine the
Scheme 2 C–H functionalisation to diverse β-aryl-aminopropionic acids.
Scheme 1 Common approaches to β-aryl-aminopropionic acids.
Scheme 3 Substrate scope of iridium-catalysed C–H borylation of
β-aryl-aminopropionic acids. a 1:1 : 3 mixture of regioisomers (2a: 4-sub-
stitued:3,5-substituted), b 2:1 mixture of regioisomers (2c: 3,4-substi-
tuted), c borylated product (R1 = Bpin) unstable to column chromato-
graphy; yield over two steps following Suzuki coupling with p-nitroiodo-
benzene to yield product 2k (R1 = p-nitrophenyl), d reaction conducted
at room temperature.
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dimer ([Ir(OCH3)(COD)]2) was chosen as the catalyst with bis
(pinacolato)diboron (B2pin2) as the boron source. We evalu-
ated three solvents (MTBE, THF and iPrNEt2) with two ligands
– 4-4′-di-tert-butyl-2,2′-bipyridine (dtbpy) and 3,4,7,8-tetra-
methyl-1,10-phenanthroline (tmphen). The reactions were
heated at 80 °C for 24 h and a qualitative assessment of con-
version determined by LCMS. The reaction did not reach com-
pletion when iPrNEt2 was used a solvent. Conversion was com-
parable for both ligands and when ether solvents were used.
Under standard heating conditions, shortening the reaction
time from 24 h reduced the conversion, but complete conver-
sion could be achieved using microwave irradiation in three
hours. Based on this screen we selected MTBE and dtbpy to
Scheme 4 Iridium-catalysed C–H borylation of enantiopure β-aryl-aminopropionic acids.
Scheme 5 One-pot functionalisation of BPin-β-aryl-aminopropionic acids. Reagents and conditions: (a) Standard conditions Scheme 2; (b)
Oxone®, aq. acetone, r.t., 0.75 h, 3 = 52%, 4 = 77%, 5 = 33%, 6 = 92% over two steps; (c) 1-iodo-4-nitrobenzene, Pd(dppf )·CH2Cl2, K3PO4, 1,2-
DME : H2O, 70 °C, 4.5 h, 93% over two steps; (d) phenol, CuOAc2, B(OH)3, 4 Å molecular sieves, 70 °C, 16 h, 8 = 36%, 9 = 34% over two steps; (e) 1,4-
dimethylpyrazole, Cu(OAc)2, B(OH)3, 4 Å molecular sieves, 80 °C, 16 h, 10 = 74%, 11 = 68% over two steps; (f ) CuBr2, MeOH : H2O (2 : 1), 70 °C, 16 h,
39%; (g) i. AgOTf, NaOH, MeOH, 0 °C, 0.5 h; ii. Selectfluor®, 3 Å MS, acetone, r.t., 3 h, 59%.
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pair with ([Ir(OCH3)(COD)]2) and B2Pin2. MTBE was selected
over THF. Under these conditions a range of β-aryl-aminopro-
pionic acid derivatives were converted into the corresponding
borylated derivatives (Scheme 3). As predicted, the reaction
predominantly or exclusively yielded the 3,5-substituted pro-
ducts, in accordance with the reported directing regio-
chemistry of iridium-catalysed borylation reactions.23
The reaction of unsubstituted β-aryl-aminopropionic acid
derivative (X = H) yielded a mixture of 3- and 4-isomers along
with and 3,5-diborylated product in a ratio of 1 : 1 : 3, as deter-
mined by 1H NMR. 3-Substituted substrates were readily toler-
ated in the reaction delivering the corresponding 3,5-substi-
tuted products in 38–86% yield (Scheme 3).
3-Fluorosubstituted substrate 1c yielded a 2 : 1 mixture of 3,5
(2c) and 3,4-isomers that were inseparable by column chrom-
atography. This is consistent with observations by other
workers.20,24 The borylated products were stable and could be
readily purified by column chromatography to isolate them.
Furthermore, the 3-trifluoromethyl 2f and 3-bromo 2h deriva-
tives could be prepared on multigram scale with improved iso-
lated yields. Under the standard borylation conditions,
2-thienyl derivative 1l yielded exclusively the 3,5-diborylated
product. The 5-borylated product 2l was produced exclusively
by conducting the reaction at room temperature. C–H boryla-
tion of the 3-pyridyl derivative 1k yielded the desired product,
however, attempts to purify the compound by chromatography
resulted in protodeborylation and recovery of starting material
1k. The yield reported is for the two-step procedure, involving
Suzuki–Miyaura coupling of the unstable boronate ester with
4-nitroiodobenzene (R1 = 4-nitrophenyl). When the enantio-
enriched substrate (S)-1f was subjected to C–H borylation fol-
lowed by oxidation, phenol (S)-3 was obtained with an 97% ee
indicating no racemisation occurs in the borylation process
(Scheme 4).
To demonstrate the versatility of these β-aryl-aminopropio-
nic acid boronate derivatives in synthesis we have exemplified
their applicability in typical reactions used in the synthesis of
biologically active molecules (Scheme 5). In each example, the
3-substituted β-aryl-aminopropionic acid derivative was bory-
lated under the previously described conditions and then tele-
scoped into functionalisation without purification of the boro-
nate. Oxidation of the boronate with aqueous Oxone® pro-
vided the phenols 3–6.16 3-Trifluoromethyl derivative 1h was
borylated and transformed into biaryl ether 7 under standard
Suzuki–Miyaura conditions. Attempts to alkylate the phenols
under standard conditions (RBr, Cs2CO3) were unsuccessful,
resulting in ester hydrolysis and transesterification only. To
circumvent this and access ether containing products we uti-
lised the Chan–Lam coupling to provide phenyl ethers 8 and
9.25 The Chan–Lam coupling was also an effective method-
ology to access N-linked heteraraomatic β-aryl-aminopropionic
acid derivatives, the 1,3-dimethylpyrazole derivates 10 and 11
were accessed in 74 and 68% yield respectively over two
steps.26 These transformations are further examples of the
Chan–Lam coupling as a viable sustainable alternative to Pd-
catalysed etherification and amination and are compatible
with tandem iridium borylation. Bromination of 2i with CuBr2
provided the 3-bromo-5-tert-butyl derivative 12, this motif is
featured in recently reported selective integrin antagonists.27,28
3-Bromo-5-fluoroderivative 13 was prepared via metallation of
the intermediate boronate to the organosilver reagent and
reaction with Selectfluor®.29
While tert-butoxycarbonyl groups present a robust, stable
protecting group for the substrates, further N-functionalisation
requires deprotection before further reaction. To demonstrate
the utility of the C–H borylation in peptidomimetics, we
replaced the tert-butoxycarbonyl group with an α-amino acid
(Scheme 6). Under the established C–H borylation conditions
the amino acid derived substrates 14a–c were converted to the
corresponding dipeptide boronates 15a–c in good yield
showing the tolerance of the conditions to more complex con-
ditions with additional hydrogen bond donors.
Finally, we used this C–H borylation strategy to prepare a
reported selective integrin antagonist.27,28 Utilising the C–H
borylation strategy to prepare 3-bromo-5-tert-butyl derivative 12
(Scheme 5) we converted this through to dipeptide 16 by
amide coupling with Boc-glycine in 50% yield (Scheme 7).
Further acidic deprotection and coupling with 3-guanidino-
benzoic acid and final ester hydrolysis provided the integrin
antagonist 17. While comparable in step count to the reported,
this approach allows installation of the stereocenter by
Reformatsky addition of ethyl bromozincacetate to the chiral
sulfinamide, obviating a chiral HPLC separation as previously
reported. The reported synthetic procedures for similar com-
Scheme 6 Iridium-catalysed C–H borylation of β-aryl-aminopropionic
dipeptides. AA = amino acid. a Extended reaction time of 6 h.
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pounds require a bespoke aldehyde synthesis for each target
compound, whereas a C–H borylation strategy allows a more
sustainable synthesis of similar analogs by functionalising a
common intermediate.
In conclusion, we have developed an efficient iridium-cata-
lysed C–H borylation procedure of β-aryl- and heteroaryl-ami-
nopropionic acids and explored the scope of the procedure
with respect to functional group tolerance and retention of
enantiointegrity. We have further explored the C–H borylation
procedure in dipeptide substrates further demonstrating its
synthetic utility. By applying telescoped “one-pot” reaction
conditions we have shown that the C–H borylation approach
allows an effective route to diversely functionalised β-aryl-ami-
nopropionic acids across chemical space relevant to medicinal
chemistry.
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